A Phase I Dose-Escalation Trial of Oral Hydroxychloroquine Plus Oral Sorafenib to Treat Patients With Refractory or Relapsed Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 29 Mar 2016
At a glance
- Drugs Hydroxychloroquine (Primary) ; Sorafenib
- Indications Solid tumours
- Focus Adverse reactions
- 08 Oct 2015 Status changed from active, no longer recruiting to completed, as reported by VG Life Sciences media release.
- 04 Sep 2014 Status changed from recruiting to active, no longer recruiting, as reported in a VG Life Sciences media release.
- 04 Sep 2014 Interim results added from the media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History